New Zealand - English - Medsafe (Medicines Safety Authority)

eisai new zealand limited - lenvatinib mesilate 4.9mg equivalent to lenvatinib 4mg - capsule - 4 mg - active: lenvatinib mesilate 4.9mg equivalent to lenvatinib 4mg excipient: calcium carbonate hyprolose as 25mg low-substituted hydroxypropyl cellulose + 3mg hydroxypropylcellulose hypromellose iron oxide black iron oxide red iron oxide yellow mannitol microcrystalline cellulose potassium hydroxide propylene glycol purified talc shellac titanium dioxide - lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

eisai new zealand limited - perampanel hemisesquihydrate 0.52 mg/ml equivalent to perampanel 0.5mg/ml - oral suspension - 2 mg/4ml - active: perampanel hemisesquihydrate 0.52 mg/ml equivalent to perampanel 0.5mg/ml excipient: avicel rc-591 citric acid poloxamer 188 purified water simethicone emulsion q7-2587 sodium benzoate sorbitol - fycompa is indicated for the adjunctive treatment of: partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy. primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eisai (malaysia) sdn bhd (18039-d) - lemborexant -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eisai (malaysia) sdn bhd (18039-d) - lemborexant -

European Union - English - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastic agents - panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (aids)-related kaposi's sarcoma (ks) when:lesions are not ulcerated or lymphoedematous, and;treatment of visceral ks is not required, and;lesions are not responding to systemic antiretroviral therapy, and;radiotherapy or chemotherapy are not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 0.52 mg/ml (equivalent: perampanel, qty 0.5 mg/ml) - oral liquid, suspension - excipient ingredients: poloxamer; sodium benzoate; sorbitol solution (70 per cent) (crystallising); citric acid; polysorbate 65; methylcellulose; benzoic acid; sorbic acid; sulfuric acid; purified water; dimeticone 500; silicon dioxide; peg-40 stearate; microcrystalline cellulose; carmellose sodium - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Israel - English - Ministry of Health

eisai israel ltd., israel - rufinamide - film coated tablets - rufinamide 200 mg - rufinamide - rufinamide - inovelon is indicated as adjunctive therapy in the treatment of seizures associated with lennox gastaut syndrome in patients 1 year of age and older.

Israel - English - Ministry of Health

eisai israel ltd., israel - rufinamide - film coated tablets - rufinamide 400 mg - rufinamide - rufinamide - inovelon is indicated as adjunctive therapy in the treatment of seizures associated with lennox gastaut syndrome in patients 1 year of age and older.

Israel - English - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - film coated tablets - perampanel as anhydrous 2 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 4 years and older.fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy..

Israel - English - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - film coated tablets - perampanel as anhydrous 4 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 4 years and older.fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy..